Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ITGAL | P20701 | 8/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 7/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 7/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904467 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2904336 | 0.91 | MEN1 (0.51) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2904334 | 0.91 | MEN1 (0.51) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2902775 | 0.89 | ITGB2 (0.51) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2902774 | 0.89 | ITGB2 (0.51) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2902131 | 0.86 | MEN1 (0.53) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2897190 | 0.86 | MEN1 (0.56) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2902128 | 0.86 | MEN1 (0.53) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2897188 | 0.86 | MEN1 (0.56) | ALDH1A1MEN1KMT2ALMNAITGAL | |
| SCHEMBL2903456 | 0.85 | CCR2 (0.51) | ALDH1A1MEN1KMT2ALMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010506-B1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2010506-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007122103-A1 | DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249589-A1 | Novel diazepan derivatives | CCR3, CCR1, CCR10 | ALDH1A1 2871/4885MEN1 2072/4885KMT2A 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.